Gilead Sciences, Inc. – NASDAQ:GILD
Gilead Sciences stock price today
$117.6
+23.48
+24.96%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Gilead Sciences stock price monthly change
+34.52%
month
Gilead Sciences stock price quarterly change
+34.52%
quarter
Gilead Sciences stock price yearly change
+17.10%
year
Gilead Sciences key metrics
Market Cap | 114.84B |
Enterprise value | 135.49B |
P/E | 931.39 |
EV/Sales | 4.78 |
EV/EBITDA | 34.57 |
Price/Sales | 4.14 |
Price/Book | 6.35 |
PEG ratio | 440.08 |
EPS | 0.4 |
Revenue | 27.45B |
EBITDA | 10.82B |
Income | 484M |
Revenue Q/Q | 5.25% |
Revenue Y/Y | 1.50% |
Profit margin | 0.45% |
Oper. margin | 29.63% |
Gross margin | 77.98% |
EBIT margin | 29.63% |
EBITDA margin | 39.44% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGilead Sciences stock price history
Gilead Sciences stock forecast
Gilead Sciences financial statements
Average Price Target
$87.18
Potential downside: -25.86%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 6.59B | 1.04B | 15.84% |
|---|---|---|---|
| Sep 2023 | 7.05B | 2.18B | 30.92% |
| Dec 2023 | 7.11B | 1.42B | 20.08% |
| Mar 2024 | 6.68B | -4.17B | -62.37% |
Paying a dividend greater than earnings.
3.27%
Yield TTM
| Payout ratio | 3862.7% |
|---|
| 2019 | 3.9% |
|---|---|
| 2020 | 4.71% |
| 2021 | 3.95% |
| 2022 | 3.44% |
| 2023 | 3.77% |
| Jun 2023 | 62337000000 | 41.24B | 66.16% |
|---|---|---|---|
| Sep 2023 | 62373000000 | 40.13B | 64.34% |
| Dec 2023 | 62125000000 | 39.37B | 63.38% |
| Mar 2024 | 56292000000 | 38.83B | 68.99% |
| Jun 2023 | 2.33B | -483M | -1.10B |
|---|---|---|---|
| Sep 2023 | 1.75B | -229M | -1.51B |
| Dec 2023 | 2.16B | -727M | -1.09B |
| Mar 2024 | 2.21B | -2.20B | -1.36B |
Gilead Sciences alternative data
Gilead Sciences Social Media Accounts
What are followers?
+0.71%
month
| Sep 2023 | 25711 |
|---|
+2.89%
month
| May 2025 | 13842 |
|---|---|
| Jul 2025 | 14681 |
| Aug 2025 | 15105 |
Areas of Focus
| 19 Feb 2023 | 46 | 0 | 0 |
|---|---|---|---|
| 26 Feb 2023 | 45 | 0 | 1 |
| 5 Mar 2023 | 47 | 0 | 0 |
| 12 Mar 2023 | 47 | 0 | 0 |
| 19 Mar 2023 | 50 | 0 | 0 |
| 26 Mar 2023 | 49 | 0 | 1 |
| 2 Apr 2023 | 49 | 0 | 1 |
| 9 Apr 2023 | 51 | 0 | 1 |
| 16 Apr 2023 | 52 | 0 | 1 |
| 23 Apr 2023 | 49 | 0 | 1 |
| 30 Apr 2023 | 50 | 0 | 1 |
| 7 May 2023 | 45 | 0 | 1 |
| 14 May 2023 | 44 | 0 | 1 |
| 21 May 2023 | 49 | 0 | 1 |
| 28 May 2023 | 50 | 0 | 1 |
| 4 Jun 2023 | 51 | 0 | 1 |
| 11 Jun 2023 | 68 | 0 | 1 |
| 18 Jun 2023 | 59 | 0 | 0 |
| 25 Jun 2023 | 58 | 0 | 0 |
| 2 Jul 2023 | 47 | 0 | 0 |
Gilead Sciences
| 21 May 2023 | 7 |
|---|---|
| 28 May 2023 | 8 |
| 4 Jun 2023 | 6 |
| 11 Jun 2023 | 6 |
| 18 Jun 2023 | 5 |
| 25 Jun 2023 | 8 |
| 2 Jul 2023 | 5 |
| 9 Jul 2023 | 7 |
| 16 Jul 2023 | 10 |
| 23 Jul 2023 | 6 |
| 30 Jul 2023 | 12 |
| 6 Aug 2023 | 8 |
| 13 Aug 2023 | 5 |
| 20 Aug 2023 | 5 |
| 27 Aug 2023 | 5 |
| 3 Sep 2023 | 3 |
| 10 Sep 2023 | 5 |
| 17 Sep 2023 | 5 |
| 24 Sep 2023 | 3 |
| 1 Oct 2023 | 4 |
Gilead Sciences Covid-19 Product
| 4 Aug 2024 | 10 |
|---|---|
| 11 Aug 2024 | 7 |
| 18 Aug 2024 | 9 |
| 25 Aug 2024 | 12 |
| 1 Sep 2024 | 10 |
| 8 Sep 2024 | 11 |
| 15 Sep 2024 | 11 |
| 22 Sep 2024 | 18 |
| 29 Sep 2024 | 31 |
| 6 Oct 2024 | 29 |
| 13 Oct 2024 | 100 |
| 20 Oct 2024 | 56 |
| 27 Oct 2024 | 45 |
| 3 Nov 2024 | 43 |
| 10 Nov 2024 | 42 |
| 17 Nov 2024 | 32 |
| 24 Nov 2024 | 30 |
| 1 Dec 2024 | 31 |
| 8 Dec 2024 | 26 |
| 15 Dec 2024 | 21 |
Gilead Sciences HIV Products
| 4 Aug 2024 | 40 | 8 | 55 | 0 | 9 |
|---|---|---|---|---|---|
| 11 Aug 2024 | 39 | 7 | 36 | 0 | 8 |
| 18 Aug 2024 | 42 | 7 | 28 | 0 | 10 |
| 25 Aug 2024 | 40 | 7 | 27 | 0 | 9 |
| 1 Sep 2024 | 41 | 6 | 41 | 0 | 10 |
| 8 Sep 2024 | 48 | 9 | 55 | 0 | 9 |
| 15 Sep 2024 | 42 | 6 | 33 | 0 | 10 |
| 22 Sep 2024 | 42 | 7 | 23 | 0 | 8 |
| 29 Sep 2024 | 46 | 6 | 30 | 0 | 7 |
| 6 Oct 2024 | 43 | 8 | 29 | 0 | 7 |
| 13 Oct 2024 | 47 | 5 | 46 | 0 | 10 |
| 20 Oct 2024 | 37 | 5 | 36 | 0 | 9 |
| 27 Oct 2024 | 39 | 5 | 27 | 0 | 7 |
| 3 Nov 2024 | 45 | 8 | 26 | 0 | 7 |
| 10 Nov 2024 | 48 | 6 | 24 | 0 | 8 |
| 17 Nov 2024 | 36 | 7 | 22 | 0 | 8 |
| 24 Nov 2024 | 45 | 6 | 26 | 0 | 8 |
| 1 Dec 2024 | 45 | 6 | 28 | 0 | 10 |
| 8 Dec 2024 | 43 | 7 | 33 | 0 | 8 |
| 15 Dec 2024 | 40 | 5 | 27 | 0 | 6 |
Gilead Sciences Oncology Products
| 19 Feb 2023 | 18 | 37 | 32 | 0 |
|---|---|---|---|---|
| 26 Feb 2023 | 13 | 17 | 25 | 0 |
| 5 Mar 2023 | 16 | 25 | 33 | 0 |
| 12 Mar 2023 | 16 | 24 | 28 | 7 |
| 19 Mar 2023 | 5 | 21 | 21 | 5 |
| 26 Mar 2023 | 8 | 100 | 29 | 7 |
| 2 Apr 2023 | 12 | 46 | 35 | 0 |
| 9 Apr 2023 | 7 | 34 | 17 | 0 |
| 16 Apr 2023 | 23 | 12 | 24 | 13 |
| 23 Apr 2023 | 5 | 27 | 32 | 6 |
| 30 Apr 2023 | 18 | 17 | 27 | 0 |
| 7 May 2023 | 14 | 32 | 29 | 5 |
| 14 May 2023 | 9 | 20 | 27 | 3 |
| 21 May 2023 | 12 | 29 | 25 | 9 |
| 28 May 2023 | 10 | 33 | 12 | 5 |
| 4 Jun 2023 | 0 | 16 | 19 | 7 |
| 11 Jun 2023 | 12 | 26 | 15 | 7 |
| 18 Jun 2023 | 35 | 30 | 30 | 7 |
| 25 Jun 2023 | 16 | 28 | 24 | 0 |
| 2 Jul 2023 | 7 | 24 | 20 | 14 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Sep 2023 | 283 |
|---|---|
| Oct 2023 | 365 |
| Nov 2023 | 389 |
| Dec 2023 | 345 |
| Jan 2024 | 356 |
| Feb 2024 | 334 |
| Apr 2024 | 331 |
| May 2024 | 308 |
| Jun 2024 | 296 |
| Jul 2024 | 299 |
| Dec 2024 | 410 |
| Jan 2025 | 487 |
| Feb 2025 | 426 |
| May 2025 | 360 |
| Jul 2025 | 327 |
| Aug 2025 | 277 |
| Sep 2023 | 17,000 |
|---|---|
| Oct 2023 | 17,000 |
| Nov 2023 | 17,000 |
| Dec 2023 | 17,000 |
| Jan 2024 | 17,000 |
| Feb 2024 | 17,000 |
| Apr 2024 | 18,000 |
| May 2024 | 18,000 |
| Jun 2024 | 18,000 |
| Jul 2024 | 18,000 |
Gilead Sciences other data
77.29%
-2.56%
of GILD is owned by hedge funds
1.53K
-96
975.42M
-32.27M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 10230 |
| Apr 2024 | 0 | 2000 |
| Jul 2024 | 0 | 2000 |
| Aug 2024 | 0 | 15003 |
| Sep 2024 | 0 | 50603 |
| Oct 2024 | 0 | 2000 |
| Nov 2024 | 0 | 450234 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | PATTERSON SANDRA officer: SVP, Controllership | Common Stock | 157 | N/A | N/A | ||
Option | PATTERSON SANDRA officer: SVP, Controllership | Restricted Stock Unit | 157 | N/A | N/A | ||
Option | PATTERSON SANDRA officer: SVP, Controllership | Common Stock | 901 | N/A | N/A | ||
Option | PATTERSON SANDRA officer: SVP, Controllership | Restricted Stock Unit | 901 | N/A | N/A | ||
Option | PARSEY MERDAD officer: Chief Me.. | Common Stock | 3,820 | N/A | N/A | ||
Option | MERCIER JOHANNA officer: Chief Co.. | Restricted Stock Unit | 3,752 | N/A | N/A | ||
Option | DICKINSON ANDREW D officer: Chief Fi.. | Common Stock | 3,640 | N/A | N/A | ||
Option | DICKINSON ANDREW D officer: Chief Fi.. | Restricted Stock Unit | 3,640 | N/A | N/A | ||
Option | TELMAN DEBORAH H officer: EVP, Corporate Affairs.. | Restricted Stock Unit | 639 | N/A | N/A | ||
Option | TELMAN DEBORAH H officer: EVP, Corporate Affairs.. | Common Stock | 639 | N/A | N/A |
| Patent |
|---|
Application Filling date: 27 Jan 2022 Issue date: 8 Sep 2022 |
Application Filling date: 16 Feb 2022 Issue date: 1 Sep 2022 |
Application Filling date: 26 Jan 2022 Issue date: 25 Aug 2022 |
Grant Design: Blister pack Filling date: 6 May 2021 Issue date: 23 Aug 2022 |
Grant Filling date: 14 Oct 2020 Issue date: 23 Aug 2022 |
Grant Filling date: 20 May 2020 Issue date: 23 Aug 2022 |
Application Filling date: 17 Jul 2020 Issue date: 18 Aug 2022 |
Application Filling date: 11 Jun 2020 Issue date: 18 Aug 2022 |
Grant Design: Blister pack Filling date: 6 May 2021 Issue date: 16 Aug 2022 |
Application Filling date: 26 Jan 2022 Issue date: 11 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 25 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Gilead Sciences' Best Days May Be Ahead - Here's Why
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
-
What's the price of Gilead Sciences stock today?
One share of Gilead Sciences stock can currently be purchased for approximately $117.6.
-
When is Gilead Sciences's next earnings date?
Unfortunately, Gilead Sciences's (GILD) next earnings date is currently unknown.
-
Does Gilead Sciences pay dividends?
Yes, Gilead Sciences pays dividends and its trailing 12-month yield is 3.27% with 3863% payout ratio.It means that the company is paying a dividend greater than earnings. The last Gilead Sciences stock dividend of $0.71 was paid on 30 Dec 2021.
-
How much money does Gilead Sciences make?
Gilead Sciences has a market capitalization of 114.84B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 0.6% to 27.12B US dollars.
-
What is Gilead Sciences's stock symbol?
Gilead Sciences, Inc. is traded on the NASDAQ under the ticker symbol "GILD".
-
What is Gilead Sciences's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Gilead Sciences?
Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Gilead Sciences's key executives?
Gilead Sciences's management team includes the following people:
- Mr. Daniel P. O'Day Chairman & Chief Executive Officer(age: 61, pay: $7,480,000)
- Ms. Johanna Mercier Chief Commercial Officer(age: 55, pay: $4,860,000)
- Dr. Merdad V. Parsey M.D., Ph.D. Chief Medical Officer(age: 62, pay: $3,850,000)
- Mr. Brett A. Pletcher Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec.(age: 57, pay: $2,710,000)
- Mr. Andrew D. Dickinson Executive Vice President & Chief Financial Officer(age: 55, pay: $2,710,000)
-
How many employees does Gilead Sciences have?
As Jul 2024, Gilead Sciences employs 18,000 workers.
-
When Gilead Sciences went public?
Gilead Sciences, Inc. is publicly traded company for more then 33 years since IPO on 22 Jan 1992.
-
What is Gilead Sciences's official website?
The official website for Gilead Sciences is gilead.com.
-
Where are Gilead Sciences's headquarters?
Gilead Sciences is headquartered at 333 Lakeside Drive, Foster City, CA.
-
How can i contact Gilead Sciences?
Gilead Sciences's mailing address is 333 Lakeside Drive, Foster City, CA and company can be reached via phone at +65 05743000.
-
What is Gilead Sciences stock forecast & price target?
Based on 8 Wall Street analysts` predicted price targets for Gilead Sciences in the last 12 months, the avarage price target is $87.18. The average price target represents a -25.86% change from the last price of $117.6.
Gilead Sciences company profile:
Gilead Sciences, Inc.
gilead.comExchange:
NASDAQ
Full time employees:
18,000
Industry:
Drug Manufacturers - General
Sector:
Healthcare
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
333 Lakeside Drive
Foster City, CA 94404
Foster City, CA 94404
CIK: 0000882095
ISIN: US3755581036
CUSIP: 375558103
